CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $0.15 by 261.29 percent. This is a 24.24 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $77.000 thousand which missed the analyst consensus estimate of $4.845 million by 98.41 percent. This is a 1.83K percent increase over sales of $4.000 thousand the same period last year.